Purespring Therapeutics Secures £80M ($105M) Series B Funding to Advance IgAN Gene Therapy into Clinical Trials

Funding:
Purespring Therapeutics has raised £80M ($105M) in a Series B funding round led by Sofinnova Partners, along with Gilde Healthcare, Forbion, British Patient Capital, and founding investor Syncona.

Purpose:
The funding will be used to initiate a Phase I/II clinical trial for IgA Nephropathy (IgAN), a common chronic kidney disease primarily affecting young adults.

Gene Therapy:
Purespring's lead asset, PS-002, is an experimental AAV gene therapy designed to target podocytes, specialized cells critical for proper kidney function, which are damaged in IgAN.

Pipeline:
Purespring has a pipeline of programs in development, including PS-001 for nephrotic syndrome and an undisclosed glomerular kidney disease program.

Market Context:
The IgAN field has seen significant attention, with major deals such as Novartis acquiring Chinook Therapeutics for $3.2B and Vertex Pharmaceuticals and Biogen making deals worth over $1B each to inherit IgAN assets.

Company Background:
Purespring Therapeutics is a London-based biotech company focused on transforming the treatment of kidney diseases through gene therapy, founded on the work of Professor Moin Saleem at the University of Bristol.